084990:KOSDAQ
Helixmith Co Ltd
₩3,200.00
arrow_downward
-1.54%(-50.00) 1D
Nov 18, 11:33:39 AM GMT+9 · KRW
search
All symbols
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for 084990...
Open
₩3,265
High
₩3,345
Low
₩3,160
Mkt. cap
147.50B
Avg. vol.
368.53K
Volume
59.53K
52-wk high
₩9,960
52-wk low
₩2,725
EPS
-₩50
Shares outstanding
46.09M
No. of employees
38
Open
₩3,265
High
₩3,345
Low
₩3,160
Mkt. cap
147.50B
Avg. vol.
368.53K
Volume
59.53K
52-wk high
₩9,960
52-wk low
₩2,725
EPS
-₩50
Shares outstanding
46.09M
No. of employees
38
News stories
From web sources and news partners
ING Sprinters
·
7 hours ago
De AEX Index breekt steun
ZeelandNet, startpagina van Zeeland
·
8 hours ago
AEX-index lager, chipbedrijven dalen in aanloop cijfers Nvidia
Nieuws.nl
·
1 day ago
AEX-index start belangrijke week voor AI-sector
De Dagelijkse Standaard
·
19 hours ago
AEX-index verder omlaag, focus op kwartaalresultaten Nvidia
Profile
Helixmith Co. LTD. is a biotechnology company located in Seoul, South Korea with US presence in San Diego. The company has an extensive gene therapy pipeline, including a non-viral plasmid DNA program for neuromuscular and ischemic disease, a CAR-T program targeting several different types of solid tumors, and an AAV vector program targeting neuromuscular diseases. Helixmith’s lead gene is Engensis, currently in phase III diabetic peripheral neuropathy in the US. Engensis is a plasmid DNA designed to simultaneously express two isoforms of hepatocyte growth factor, HGF 728 and HGF 723. In addition to DPN, Engensis is also being studied in diabetic foot ulcers, amyotrophic lateral sclerosis, coronary artery disease, claudication, and Charcot-Marie-Tooth disease. Wikipedia
About Helixmith Co Ltd
CEO-
Employees38
FoundedNov 1996
Headquarters-
SectorHealth Care
IndustryBiotechnology
Websitehelixmith.com